Teligent, Inc. (NASDAQ:TLGT)

IGI Laboratories, Inc. engages in developing, manufacturing, filling, and packaging topical semi-solid and liquid products for cosmetic, cosmeceutical, and pharmaceutical customers in the United States. The company’s products are used for various skin conditions, including the treatment of symptoms of dermatitis, acne, psoriasis, and eczema. It offers contract formulation and contract manufacturing services to a range of topical formulations, including creams, ointments, lotions, gels, and topical liquids. The company is also developing a portfolio of prescription generic formulations in topical dosage forms. IGI Laboratories, Inc., through its license agreement with Novavax, Inc., utilizes the Novasome lipid vesicle encapsulation and certain other technologies for applications in animal pharmaceuticals, biologicals, and other animal health products; foods, food applications, nutrients, and flavorings; cosmetics, consumer products, and dermatological over-the-counter and prescription products; fragrances; and chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals, and other specialty chemicals. The company was formerly known as IGI, Inc. and changed its name to IGI Laboratories, Inc. in May 2008. IGI Laboratories, Inc. was founded in 1977 and is based in Buena, New Jersey.